DEFA14A: Merck to Acquire Verona Pharma for $10 Billion, Bolstering Respiratory Portfolio with COPD Treatment Ohtuvayre

Merck announced a definitive agreement to acquire Verona Pharma for approximately $10 billion, adding Ohtuvayre, a recently FDA-approved COPD maintenance treatment, to its growing cardio-pulmonary pipeline.

Summary

• Verona Pharma plc entered into a Transaction Agreement with Merck Sharp & Dohme LLC and its wholly-owned subsidiary, Vol Holdings LLC (Bidco), for Bidco to acquire all issued and to be issued share capital of Verona Pharma.
• The acquisition will be effected through a court-sanctioned English law scheme of arrangement.
• Verona Pharma shareholders will receive $13.375 in cash for each ordinary share, and holders of American Depositary Shares (ADSs), each representing eight ordinary shares, will receive $107 in cash per ADS.
• The total transaction value is approximately $10 billion.
• All outstanding and unvested Company share options will become fully vested; in-the-money options will convert to cash based on the difference between the ADS consideration and exercise price, while out-of-the-money options will be cancelled for no consideration.
• Time-based restricted share units (RSUs) will become fully vested and convert to cash based on the ADS consideration.
• Performance-based restricted share units (PRSUs) that are earned or eligible to be earned will vest at 100% (or higher if estimated actual performance for the current quarter is greater) and convert to cash based on the ADS consideration; unearned PRSUs from prior completed quarters will be cancelled for no consideration.
• The acquisition adds Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to Merck's portfolio.
• Ohtuvayre was approved by the U.S. FDA in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
• The transaction was unanimously approved by both the Merck and Verona Pharma Boards of Directors.
• Closing is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act, Verona Pharma shareholder approval, sanction by the High Court of Justice of England and Wales, and other customary conditions.
• The transaction is expected to close in the fourth quarter of 2025.
• The purchase price will be capitalized as an intangible asset for Ohtuvayre, which will be amortized as a GAAP-only charge over the product's life.
• Directors and certain executive officers of Verona Pharma have entered into a Voting Agreement to support the transaction.

Sentiment

Score: 9

Explanation: The acquisition offers a substantial premium to Verona Pharma shareholders and strategically enhances Merck's portfolio with a first-in-class, recently approved COPD treatment, Ohtuvayre, which has demonstrated strong initial market uptake. This is a highly positive development for Verona Pharma shareholders and a significant strategic move for Merck.

Positives

• Verona Pharma shareholders will receive a substantial cash premium of $107 per ADS, representing a significant return on their investment.
• Merck will expand its growing cardio-pulmonary pipeline and portfolio by acquiring Ohtuvayre, a first-in-class treatment for COPD.
• Ohtuvayre, approved by the FDA in June 2024, is the first novel inhaled mechanism for COPD treatment in over 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects, addressing an important unmet patient need.
• The acquisition is expected to drive nearand long-term growth and deliver value for Merck shareholders.
• Merck's extensive commercial footprint and industry-leading clinical capabilities are anticipated to accelerate Ohtuvayre's market reach and potential.
• The transaction received unanimous approval from the Boards of Directors of both Merck and Verona Pharma, indicating strong internal support.

Negatives

• Verona Pharma shareholders will forgo any potential future upside from the company's independent operations and Ohtuvayre's commercial success beyond the acquisition price.
• Company share options with an exercise price equal to or greater than the ADS Consideration ($107) will be automatically cancelled for no consideration.
• Performance-based restricted share units that were eligible to be earned in a performance quarter completed prior to the Effective Time, but which were not earned, will be automatically cancelled for no consideration.
• The transaction carries a risk of shareholder litigation, which could result in significant defense costs, indemnification, and liability.

Risks

• Uncertainties exist regarding the precise timing of the proposed transaction's completion.
• There is a risk that competing offers or alternative acquisition proposals for Verona Pharma may emerge.
• The consummation of the transaction is contingent upon the satisfaction or waiver of various conditions, including Verona Pharma shareholder approval, sanction by the High Court of Justice of England and Wales, and regulatory approvals under antitrust laws (e.g., HSR Act).
• The announcement and pendency of the transaction may disrupt Verona Pharma's business operations and relationships with customers, suppliers, and other partners.
• Shareholder litigation related to the transaction could lead to significant costs for defense, indemnification, and potential liabilities.
• Verona Pharma's future success is dependent on the successful commercialization of Ohtuvayre, and its market acceptance as a COPD treatment remains uncertain.
• Risks inherent in pharmaceutical product development, including the ongoing development of ensifentrine for other indications and other product candidates, and the uncertainty of clinical success.
• General industry conditions and competitive pressures could impact the value and success of Ohtuvayre.
• General economic factors, including fluctuations in interest rates and currency exchange rates, could affect the transaction or future performance.
• The impact of pharmaceutical industry regulation and healthcare legislation, both in the United States and internationally, poses regulatory risks.
• Global trends toward healthcare cost containment could affect Ohtuvayre's commercial prospects.
• Technological advances, new products, and patents obtained by competitors could diminish Ohtuvayre's market position.
• Manufacturing difficulties or delays could impede product supply.
• Financial instability in international economies and sovereign risk could impact operations.
• Dependence on the effectiveness of patents and other intellectual property protections for innovative products is a key risk.
• Exposure to litigation, including patent litigation, and/or regulatory actions could negatively impact the company.

Future Outlook

The acquisition is expected to drive nearand long-term growth for Merck by integrating Ohtuvayre, a recently FDA-approved COPD treatment, into its portfolio. Ohtuvayre is also being evaluated in clinical trials for non-cystic fibrosis bronchiectasis, indicating potential for future expansion into other respiratory diseases.

Management Comments

• Robert M. Davis, Chairman and CEO of Merck: "This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ability to execute on our science-led and value-driven business development strategy. Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering nearand long-term growth as well as value for shareholders. This novel, first-in-class treatment addresses an important unmet need for COPD patients persistently symptomatic based on its unique combination of bronchodilatory and non-steroidal anti-inflammatory effects. We look forward to welcoming the talented Verona Pharma team to Merck."
• David Zaccardelli, President and CEO of Verona Pharma: "Today’s announced agreement with Merck is the culmination of years of focus and determination by the Verona Pharma team advancing Ohtuvayre, the first novel inhaled mechanism for the maintenance treatment of COPD in two decades. Since launching Ohtuvayre in August 2024 we have seen rapid and accelerating uptake in the U.S. We believe Merck’s commercial footprint and industry-leading clinical capabilities will help accelerate the potential of Ohtuvayre to reach more patients living with COPD. This agreement will enable the strong launch trajectory of this important medicine and provides value to Verona Pharma shareholders."

Industry Context

This acquisition exemplifies the ongoing trend of large pharmaceutical companies acquiring smaller biopharmaceutical firms to enhance their product pipelines with innovative, recently approved therapies. Ohtuvayre's status as a 'first-in-class' treatment with a dual mechanism of action (bronchodilator and non-steroidal anti-inflammatory) is particularly significant, as the COPD treatment landscape has seen limited novel inhaled mechanisms in over two decades. This strategic move strengthens Merck's position in the cardio-pulmonary disease market, allowing it to leverage its extensive commercial and clinical infrastructure to maximize Ohtuvayre's market penetration and reach a broader patient population.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the acquisition's financial or operational outcomes against global industry benchmarks. The focus is on the strategic value of Ohtuvayre as a 'first-in-class' treatment and its unique mechanism of action in the COPD market.
• The acquisition price of approximately $10 billion for Verona Pharma, a company with a recently approved and launched product (Ohtuvayre), suggests a valuation based on the perceived high potential and unmet need in the COPD market, aligning with industry trends of significant premiums for novel, de-risked assets.

Management Changes

Corporate Governance

Legal Proceedings

• The Company will promptly advise Parent of any Legal Proceeding commenced after the agreement date against the Company or its directors/officers by any Company Shareholder relating to the transaction.
• The Company will provide Parent with the opportunity to consult regarding, and participate in, the defense of any such Legal Proceeding (subject to a joint defense agreement).
• The Company may not enter into any settlement agreement or offer/agree to any mooting disclosure in respect of such Legal Proceeding without Parent's prior written consent.

Related Party Transactions

• Directors and certain executive officers of Verona Pharma entered into a Voting Agreement with Parent and the Company, committing to support the Transaction and vote in favor of the Scheme of Arrangement and the Company Shareholder Resolution.

Stakeholder Impact

• Shareholders: Will receive a significant cash premium for their shares, providing immediate liquidity and a favorable return. However, those with out-of-the-money options or unearned PRSUs from prior completed quarters will see them cancelled without consideration.
• Employees: Current employees will receive comparable base compensation, short-term cash incentives, and benefits for 12 months post-acquisition. Service credit for vesting and eligibility in Parent's plans will be provided, and a 401(k) plan transition is planned. This aims to ensure continuity and stability for the workforce.
• Customers/Patients: Expected to benefit from Merck's larger commercial footprint and clinical capabilities, which are anticipated to accelerate the reach of Ohtuvayre to more patients living with COPD.
• Management: Verona Pharma's directors and certain executive officers have committed to supporting the transaction, and the board structure will change post-acquisition with new directors appointed by Merck.

Next Steps

• Verona Pharma will prepare and file a proxy statement (Schedule 14A) with the U.S. Securities and Exchange Commission (SEC).
• Verona Pharma will make necessary applications to the High Court of Justice of England and Wales to sanction the Scheme of Arrangement.
• Verona Pharma will convene and hold the Scheme Meeting and the Company General Meeting for shareholder approvals.
• Merck and Verona Pharma will work to obtain all necessary regulatory approvals, including under the HSR Act and other Antitrust Laws.
• The closing of the transaction is expected in the fourth quarter of 2025.
• Merck will integrate Verona Pharma's operations and Ohtuvayre into its existing portfolio.
• Continued evaluation of Ohtuvayre in clinical trials for non-cystic fibrosis bronchiectasis.

Key Dates

Recommendation

Keywords

Verona Pharma, Merck, acquisition, biopharmaceutical, COPD, Ohtuvayre, ensifentrine, PDE3, PDE4, FDA approval, pharmaceutical, healthcare, M&A, scheme of arrangement, drug development, respiratory diseases